Document is current

Article History

Received: 4 June 2024

Accepted: 9 September 2024

First Online: 2 October 2024

Declarations

:

: Stefan S. Bielack has participated in advisory boards for Eisa, MAP Biopharma, Roche and Y-mAbs Therapeutics; and, has acted as a consultant for SERB S.A.S.Christopher P. Fox has provided consultancy/participated in advisory boards for AbbVie, AstraZeneca, Atarabio, BMS, GenMab, Gilead/Kite, Incyte, Janssen, Lilly, Morphosys, Ono, Roche, SERB, SOBI and Takeda; has contributed to remunerated educational activities for AbbVie, Kite/Gilead, Incyte, Janssen, Roche and Takeda; has received travel support from Kite/Gilead and Roche; and, has received research funding from BeiGene.Thais Murciano has received speaker fees from Alexion Farma, Amgen and Novartis; has received support for meeting attendance from Novartis; and, has contributed to advisory boards for Amgen, BTG Pharmaceuticals, Novartis and Sobi.Wendy Osborne has contributed to advisory boards from AbbVie, AstraZeneca, Autolus, Beigene, Incyte, Janssen, Kite Gilead, Kyowa Kirin, MSD, Novartis, Roche, Servier, Sobi, Syneos and Takeda; has received speaker fees from AbbVie, AstraZeneca, Incyte, Janssen, Kite Gilead, Kyowa Kirin, Novartis, Pfizer, Roche and Takeda; has received support for meeting attendance from Kite Gilead, Novartis, Roche and Takeda; and, has participated on a data monitoring safety committee for Syneos.Pier Luigi Zinzani has provided consultancy to EUSA Pharma, MSD and Novartis; has participated in speakers’ bureau for AstraZeneca, Beigene, BMS, Celltrion, EUSA Pharma, Gilead, Incyte, Janssen-Cilag, Kyowa Kirin, MSD, Novartis, Roche, Servier and Takeda; and, has contributed to advisory boards for ADC Therapeutics, AstraZeneca, Beigene, BMS, Celltrion, EUSA Pharma, Gilead, Incyte, Janssen-Cilag, Kyowa Kirin, MSD, Novartis, Roche, Sandoz, Secura Bio, Servier and Takeda.Carmelo Rizzari has received honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events, as well as for participating on advisory boards, from Amgen, BTG Specialty Pharmaceuticals, Clinigen and Jazz Pharmaceuticals. Stefan Schwartz has received a study research grant from BTG Specialty Pharmaceuticals; has received speaker honoraria from Amgen and CSi Hamburg; and, has contributed to advisory boards for Amgen, Pfizer and SERB S.A.S.Carole Soussain and Caroline Houillier declare no further conflicts of interest.